-
Mashup Score: 1De Novo Oligometastatic Breast Cancer - 7 month(s) ago
De novo oligometastatic breast cancer, a unique disease needing new treatment paradigms.
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease - 8 month(s) ago
Recent therapeutic advances have led to improved patient survival in many cancer settings. Although prolongation of survival remains the ultimate goal of cancer treatment, the availability of effective salvage therapies could make definitive phase III trials with primary overall survival (OS) end points difficult to complete in a timely manner. Therefore, to accelerate development of new therapies, many phase III trials of new cancer therapies are now designed with intermediate primary end points (eg, progression-free survival in the metastatic setting) with OS designated as a secondary end point. We review recently published phase III trials and assess contemporary practices for designing and reporting OS as a secondary end point. We then provide design and reporting recommendations for trials with OS as a secondary end point to safeguard OS data integrity and optimize access to the OS data for patient, clinician, and public-health stakeholders.
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Supported by NIH UM1CA186690-06, P50CA254865-01A1, P30CA047904-32, and R01DE031729-01A1 (J.J.L.). Administrative support: Jason J. Luke AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscrip
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
AUTHOR’S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless othe rwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/autho
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7
Financial support: Alexander R.A. Anderson AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.or
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms - 10 month(s) ago
Supported by Arnold Ventures. Financial support: Aaron S. Kesselheim AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unles s otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal - 10 month(s) ago
Show More *M.D. and E.E.V. contributed equally to this work as senior authors. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
We suggest approaches to reduce cancer’s employment pitfalls across diagnoses, jobs, and social vulnerability.
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Addressing Barriers to Clinical Trial Participation for Transgender People With Cancer to Improve Access and Generate Data - 1 year(s) ago
A roadmap for addressing barriers to cancer clinical trial enrollment for transgender people.
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Incorporating Information From Proxies for Patient-Centered Outcomes in Adult and Pediatric Oncology Settings - 2 year(s) ago
Priorities for proxy research to advance patient-centered outcome data collection in oncology
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
🤔 #JCO #CommentsAndControversies: De novo oligometastatic #BreastCancer, a unique disease needing new treatment paradigms: https://t.co/ZRnygP1duh #BCSM @YaleCancer @YaleBreast